MoneycontrolMoneycontrol

Buy Torrent Pharmaceuticals; target of Rs 5500: Prabhudas Lilladher

Menos de 1 minuto de lectura

Prabhudas Lilladher's research report on Torrent Pharmaceuticals

Torrent Pharma (TRP) reported in line Q2FY27 performance, with the base business EBITDA growing 20% YoY. The performance was driven by robust execution and continued momentum in the domestic franchise. The injectable semaglutide, supply disruption got resolved with stock now fully restored, management expects market share to recover following normalization of supplies. The integration of JB Chemicals & Pharma (JBCP) is progressing ahead of schedule, with cost synergies already exceeding initial expectations and revenue synergies likely to accrue from FY28E. The acquisition strengthens Torrent's leadership in high-margin chronic therapies, expands its presence across multiple therapeutic segments, and positions the company as the 5 th largest player in the Indian pharmaceutical market. Additionally, JBCP's CDMO business enhances portfolio diversification and provides an incremental long-term growth avenue.

Outlook

We expect company to achieve higher cost synergies of earlier guidance of INR 4- 4.5bn deal and expect combined entity EBIDTA to be at INR 79-80bn in FY28E. TRP trades at 21.5x EV/EBITDA on Sept 2028E for the combined business. We maintain “BUY” rating with revised TP of Rs5,500/share, valuing at 25x EV/EBITDA on Sept 2028E for combined entity.

Exención de responsabilidad

Lea el artículo completo
Disfrute de acceso ilimitado a los artículos de Moneycontrol y al resto de fuentes de noticias disponibles en TradingView.